- active not recruitingPHASE2
A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
This study looks at a new combination of existing medicines for a type of neuroendocrine tumour that has spread and hasn't been treated with chemotherapy before. It aims to see if combining pembrolizumab with chemotherapy, followed by a maintenance treatment, is safe and effective.
United Kingdom - active not recruitingPHASE3
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
This study compares a new radiation treatment (177Lu-edotreotide PRRT) with a standard drug (Everolimus) for people with certain types of advanced neuroendocrine tumours that affect the gut or pancreas. It aims to see which treatment works better and is safer.
United States · Australia · Austria - active not recruiting
Post-Authorization Long-Term Safety Study of LUTATHERA
This study looks at the long-term safety of a treatment called LUTATHERA for a type of cancer called neuroendocrine tumours. Researchers want to understand any side effects that might appear over time in patients who have received this medicine.
United States · France · Portugal - recruitingPHASE1
Lutathera and ASTX727 in Neuroendocrine Tumours
This study looks at a new way to treat neuroendocrine tumours. It checks if taking a medicine called ASTX727 before Lutathera helps Lutathera work better. Doctors will use special scans to see if this combination treatment improves how your body responds.
United Kingdom - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - active not recruitingPHASE3
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
This study looks at a new type of radiation treatment called PRRT (using Lutetium-177) for certain aggressive bowel and pancreas neuroendocrine tumours. It compares this new treatment with standard care to see if it's more effective, safer, and improves patients' quality of life.
United States · Australia · China